Literature DB >> 1911196

Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.

G Citro1, C Cucco, A Verdina, G Zupi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1911196      PMCID： PMC1977636          DOI： 10.1038/bjc.1991.345

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  17 in total

Review 1.  Multidrug resistance.

Authors:  A M van der Bliek; P Borst
Journal:  Adv Cancer Res       Date:  1989       Impact factor: 6.242

2.  Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells.

Authors:  C R Fairchild; S P Ivy; C S Kao-Shan; J Whang-Peng; N Rosen; M A Israel; P W Melera; K H Cowan; M E Goldsmith
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

3.  Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy.

Authors:  R C Lyon; J S Cohen; P J Faustino; F Megnin; C E Myers
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

Review 4.  Mechanism of multidrug resistance.

Authors:  G Bradley; P F Juranka; V Ling
Journal:  Biochim Biophys Acta       Date:  1988-08-03

5.  On the mechanism of action of lonidamine: a study on human erythrocyte membrane.

Authors:  W Malorni; G Arancia; C De Martino; A Nista; L Accinni; R Masella; A Cantafora
Journal:  Exp Mol Pathol       Date:  1988-12       Impact factor: 3.362

Review 6.  Modulation of glycolysis in neuroepithelial tumors.

Authors:  A Floridi; M G Paggi; M Fanciulli
Journal:  J Neurosurg Sci       Date:  1989 Jan-Mar       Impact factor: 2.279

7.  Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism.

Authors:  O Kaplan; G Navon; R C Lyon; P J Faustino; E J Straka; J S Cohen
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

8.  Quantitation of adriamycin content by a sensitive immunochemical assay.

Authors:  G Citro; A Verdina; R Galati; A Floridi
Journal:  Anticancer Res       Date:  1988 Jul-Aug       Impact factor: 2.480

9.  In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin.

Authors:  G Zupi; C Greco; N Laudonio; M Benassi; B Silvestrini; A Caputo
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480

10.  Phase II study of lonidamine in metastatic breast cancer.

Authors:  P Pronzato; D Amoroso; G Bertelli; P F Conte; M P Cusimano; G B Ciottoli; M Gulisano; R Lionetto; R Rosso
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640
View more
  8 in total

1.  Receptor-mediated oligodeoxynucleotides delivery by estradiol and folic acid polylysine conjugates.

Authors:  G Citro; P Ginobbi; C Szczylik
Journal:  Cytotechnology       Date:  1993-01       Impact factor: 2.058

2.  Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene.

Authors:  D Del Bufalo; A Biroccio; S Soddu; N Laudonio; C D'Angelo; A Sacchi; G Zupi
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

3.  Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.

Authors:  R V Iaffaioli; A Tortoriello; G Facchini; M Santangelo; L Bucci; L Fei; N Di Martino; G Mantovani; F Caponigro
Journal:  Breast Cancer Res Treat       Date:  1995-09       Impact factor: 4.872

4.  Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target.

Authors:  G Scambia; F O Ranelletti; P B Panici; R De Vincenzo; G Bonanno; G Ferrandina; M Piantelli; S Bussa; C Rumi; M Cianfriglia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A.

Authors:  M Clynes; A Redmond; E Moran; U Gilvarry
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

6.  Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.

Authors:  R J Popert; J R Masters; M Coptcoat; G Zupi
Journal:  Urol Res       Date:  1995

7.  Lonidamine causes inhibition of angiogenesis-related endothelial cell functions.

Authors:  Donatella Del Bufalo; Daniela Trisciuoglio; Marco Scarsella; Giulia D'Amati; Antonio Candiloro; Angela Iervolino; Carlo Leonetti; Gabriella Zupi
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

8.  Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.

Authors:  W Zoli; L Ricotti; M Dal Susino; F Barzanti; G L Frassineti; S Folli; A Tesei; F Bacci; D Amadori
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.